SRRK Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of -255.85%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Scholar Rock Holding Corp. has a consensus price target of $47.33, signalling upside risk potential of 8.79%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Scholar Rock Holding Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Scholar Rock Holding Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Scholar Rock Holding Corp. has a beta of 0.608, which suggesting that the stock is 39.233% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of --. Scholar Rock Holding Corp.'s return on equity of -142.69% beat Palatin Technologies's return on equity of --.

Scholar Rock Holding Corp. has a consensus price target of $47.33, signalling upside risk potential of 8.79%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Scholar Rock Holding Corp., analysts believe Palatin Technologies is more attractive than Scholar Rock Holding Corp..

Scholar Rock Holding Corp. has a beta of 0.608, which suggesting that the stock is 39.233% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Scholar Rock Holding Corp.'s net income of -$102.2M is higher than Palatin Technologies's net income of --. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of 38.89%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Scholar Rock Holding Corp. has a consensus price target of $47.33, signalling upside risk potential of 8.79%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that Scholar Rock Holding Corp. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Scholar Rock Holding Corp. is more attractive than Regeneron Pharmaceuticals, Inc..

Scholar Rock Holding Corp. has a beta of 0.608, which suggesting that the stock is 39.233% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.